Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jessica McCarrick

Dermatology Miami, FL Medical Doctor

NPI 1568878361 CMS profile 1386652

8900 N Kendall Dr, Miami, FL 33176

Open in the dashboard

General payments

$798

19 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica McCarrick of Miami, FL is reported in the CMS Open Payments database as having received $798 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 30th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $519 14
2024 General $15 1
2023 General $128 1
2019 General $136 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica McCarrick
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Jessica McCarrick were reported at $519. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Jessica McCarrick Dermatology median Middle half National median
2019 $136 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $128 $607 $159–$1,674 $160
2024 $15 $751 $204–$1,903 $164
2025 $519 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $291 6 payments
  2. Lilly USA, LLC $135 3 payments
  3. Mallinckrodt Hospital Products Inc. $128 1 payment
  4. Sun Pharmaceutical Industries Inc. $109 2 payments
  5. AbbVie, Inc. $85 4 payments
  6. Regeneron Healthcare Solutions, Inc. $20 1 payment
  7. Amgen Inc. $16 1 payment
  8. Novocure Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $703 18 payments
  2. Education $95 1 payment
Products named General payments · program years 2019–2025
  1. TREMFYA $291 6 payments
  2. TALTZ $135 3 payments
  3. UVADEX $128 1 payment
  4. SIMPONI $100 3 payments
  5. SIMPONI ARIA $100 3 payments
  6. STELARA $100 3 payments
  7. SKYRIZI $61 3 payments
  8. HUMIRA $24 1 payment
  9. EBGLYSS $23 1 payment
  10. DUPIXENT $20 1 payment
  11. Other $45 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

720

Median for Dermatology: 534

Drug cost

$74,998

Median for Dermatology: $67,151

Branded share of claims

3.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 11 $38,085
Jublia Efinaconazole Brand 11 $8,768
Tacrolimus Generic 32 $5,020
Ketoconazole Generic 249 $4,816
Clobetasol Propionate Generic 38 $4,291
Calcipotriene Generic 40 $3,511
Pimecrolimus Generic 12 $3,111
Fluocinonide Generic 48 $1,830
Ammonium Lactate Generic 81 $1,578
Metronidazole Generic 18 $1,280

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$54,972

Medicare's payments for the services billed

Medicare patients

172

Average age 75

Services billed

982

100 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Arthritis 58%
Cancer 45%
Ischemic heart disease 44%
Diabetes 30%
Chronic kidney disease 22%
Atrial fibrillation 20%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record